Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3175-3185

  Ketola, Kirsi ^a   Vainio, Paula ^a   Fey, Vidal ^b   Kallioniemi, Olli ^a,b,c   Iljin, Kristiina ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ASCORBIC ACID; BICALUTAMIDE; DISULFIRAM; FLUTAMIDE; MESSENGER RNA; MONENSIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALDEHYDE DEHYDROGENASE; ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; APOPTOSIS; ASCORBIC ACID; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MONENSIN; OXIDATIVE STRESS; PROGESTERONE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TERFENADINE;

EID: 78650432857     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0368     Document Type: Article

References (58)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
2. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-4000.
3. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
4. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. Highthroughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009;15:6070-8.
5. Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008;123:2774-81.
6. Westley JW, Evans RH Jr, Sello LH, Troupe N, Liu C, Miller PA. Isolation of novel antibiotics X-14667A and X-14667B from Streptomyces cinnamonensis subsp. urethanofaciens and their characterization as 2-phenethylurethanes of monensins B and A. J Antibiot (Tokyo) 1981;34:1248-52.
7. Adovelande J, Schrevel J. Carboxylic ionophores in malaria chemotherapy: The effects of monensin and nigericin on plasmodium falciparum in vitro and plasmodium vinckei petteri in vivo. Life Sci 1996;59:PL309-15.
8. Otoguro K, Kohana A, Manabe C, Ishiyama A, Ui H, Shiomi K, et al. Potent antimalarial activities of polyether antibiotic, X-206. J Antibiot (Tokyo) 2001;54:658-63.
9. Mollenhauer HH, Morre DJ, Rowe LD. Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys Acta 1990;1031:225-46.
10. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-8.
11. Harris SE, Rong Z, Harris MA, Lubahn DB. Androgen receptor in human prostate carcinoma LNCaP/ADEP cells contains a mutation which alters the specificity of the steroid dependent transcriptional activation region. Endocrinology 1990;126(Suppl):93-7.
12. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;18: 1225-31.
13. Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, et al. hTERT-immortalized prostate epithelial and stromal-derived cells: An authentic in vitro model for differentiation and carcinogenesis. Cancer Res 2006;66:3531-40.
14. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
15. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1-25.
16. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
18. Lamb J. The connectivity map: A new tool for biomedical research. Nat Rev Cancer 2007;7:54-60.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
20. Stein BS, Bensch KG, Sussman HH. Complete inhibition of transferrin recycling by monensin in K562 cells. J Biol Chem 1984;259: 14762-72.
21. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
22. Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration- resistant prostate cancer in a mouse xenograft model. Prostate 2010;70:390-400.
23. Jangi SM, Ruiz-Larrea MB, Nicolau-Galmes F, Andollo N, Arroyo- Berdugo Y, Ortega-Martinez I, et al. Terfenadine-induced apoptosis in human melanoma cells is mediated through Ca2+ homeostasis modulation and tyrosine kinase activity, independently of H1 histamine receptors. Carcinogenesis 2008;29:500-9.
24. Diaz-Trelles R, Novelli A, Vega JA, Marini A, Fernandez-Sanchez MT. Antihistamine terfenadine potentiates NMDA receptor-mediated calcium influx, oxygen radical formation, and neuronal death. Brain Res 2000;880:17-27.
25. Han ES, Muller FL, Perez VI, Qi W, Liang H, Xi L, et al. The in vivo gene expression signature of oxidative stress. Physiol Genomics 2008;34:112-26.
26. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, et al. Identification of thioredoxin-binding protein-2/vitamin D(3) upregulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 1999;274:21645-50.
27. Wang Y, De Keulenaer GW, Lee RT. Vitamin D(3)-up-regulated protein- 1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 2002;277:26496-500.
28. Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, et al. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas 2008;36:178-86.
29. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, et al. Vitamin D3 upregulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000;164:6287-95.
30. Jimenez I, Gotteland M, Zarzuelo A, Uauy R, Speisky H. Loss of the metal binding properties of metallothionein induced by hydrogen peroxide and free radicals. Toxicology 1997;120:37-46.
31. Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: Activating transcription factor proteins and homeostasis. Gene 2001;273:1-11.
32. Huang X, Li X, Guo B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 2008;283:29795-801.
33. Whitney ML, Jefferson LS, Kimball SR. ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun 2009;379:451-5.
34. Guan L, Han B, Li Z, Hua F, Huang F, Wei W, et al. Sodium selenite induces apoptosis by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in human acute promyelocytic leukemia NB4 cells. Apoptosis 2009;14:218-25.
35. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:8031-8.
36. Davydov VV, Dobaeva NM, Bozhkov AI. Possible role of alteration of aldehyde's scavenger enzymes during aging. Exp Gerontol 2004; 39:11-6.
37. Donoho AL. Biochemical studies on the fate of monensin in animals and in the environment. J Anim Sci 1984;58:1528-39.
38. Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, et al. Monensin inhibits the growth of renal cell carcinoma cells via cell cycle arrest or apoptosis. Int J Oncol 2003;22:855-60.
39. Park WH, Kim ES, Jung CW, Kim BK, Lee YY. Monensin-mediated growth inhibition of SNU-C1 colon cancer cells via cell cycle arrest and apoptosis. Int J Oncol 2003;22:377-82.
40. Park WH, Kim ES, Kim BK, Lee YY. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis. Int J Oncol 2003;23:197-204.
41. Park WH, Seol JG, Kim ES, Kang WK, Im YH, Jung CW, et al. Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis. Br J Haematol 2002;119:400-7.
42. Pinthus JH, Bryskin I, Trachtenberg J, Lu JP, Singh G, Fridman E, et al. Androgen induces adaptation to oxidative stress in prostate cancer: Implications for treatment with radiation therapy. Neoplasia 2007;9:68-80.
43. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: Involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 2003;163:2513-22.
44. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
45. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 2007;178:1238-43; discussion 1243-4.
46. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.
47. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D, et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009;15:3979-89.
48. Ozacmak VH, Sayan H. The effects of 17beta estradiol, 17alpha estradiol and progesterone on oxidative stress biomarkers in ovariectomized female rat brain subjected to global cerebral ischemia. Physiol Res 2009;58:909-12.
49. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9.
50. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-47.
51. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 2006;21:509-19.
52. Chow JM, Liu CR, Lin CP, Lee CN, Cheng YC, Lin S, et al. Downregulation of c-myc determines sensitivity to 2-methoxyestradiolinduced apoptosis in human acute myeloid leukemia. Exp Hematol 2008;36:140-8.
53. Zhang M, Shoeb M, Goswamy J, Liu P, Xiao TL, Hogan D, et al. Overexpression of aldehyde dehydrogenase 1A1 reduces oxidationinduced toxicity in SH-SY5Y neuroblastoma cells. J Neurosci Res 2010;88:686-94.
54. Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D, et al. High aldehyde dehydrogenase activity: A novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27:2220-8.
55. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234-44.
56. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
57. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by highthroughput screening. Cell 2009;138:645-59.
58. Langston VC, Galey F, Lovell R, Buck WB. Toxicity and therapeutics of monensin: A review. Vet Med 1985;80:75-84.